JAK2 Inhibitor, Fedratinib, Inhibits P-gp Activity and Co-Treatment Induces Cytotoxicity in Antimitotic Drug-Treated P-gp Overexpressing Resistant KBV20C Cancer Cells

P-glycoprotein (P-gp) overexpression is one of the major mechanisms of multidrug resistance (MDR). Previously, co-treatment with Janus kinase 2 (JAK2) inhibitors sensitized P-gp-overexpressing drug-resistant cancer cells. In this study, we assessed the cytotoxic effects of JAK2 inhibitor, fedratinib...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	International journal of molecular sciences 2022-04, Vol.23 (9), p.4597
Hauptverfasser:	Oh, Yunmoon, Lee, Jin-Sol, Lee, Ji Sun, Park, Jae Hyeon, Kim, Hyung Sik, Yoon, Sungpil
Format:	Artikel
Sprache:	eng
Schlagworte:	Annexin V Antimitotic Agents - pharmacology Antineoplastic Agents - pharmacology Apoptosis ATP Binding Cassette Transporter, Subfamily B, Member 1 - antagonists & inhibitors ATP Binding Cassette Transporter, Subfamily B, Member 1 - genetics ATP Binding Cassette Transporter, Subfamily B, Member 1 - metabolism Autophagy Cancer Cancer therapies Cell Line, Tumor Cell viability Cytotoxicity Dimethyl sulfoxide DNA damage Drug dosages Drug resistance Drug Resistance, Neoplasm Flow cytometry G2 phase Humans Janus kinase Janus kinase 2 Janus Kinase 2 - antagonists & inhibitors Janus Kinase 2 - metabolism Janus Kinase Inhibitors - pharmacology Kinases Multidrug resistance Neoplasms - drug therapy Neoplasms - genetics P-Glycoprotein Proteins Pyrrolidines Sulfonamides Vinblastine Vincristine Vincristine - pharmacology Vinorelbine Western blotting
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!